Upper tract urothelial carcinoma · 4 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Carboplatin and Gemcitabine (GCb) Variant #01 | — | R 4 414 | 21d | — | — | 2 | R 8 829 PFS proxy | 1 |
Cisplatin and Gemcitabine (GC) Variant #01 | — | R 3 933 | 21d | — | — | 6 | R 23 595 PFS proxy | 1 |
Observation Partial | — | — | — | — | — | — | — | 2 |
Pirarubicin monotherapy Variant #01 Partial | — | — | — | — | — | ~1 | — | — |
4 of 4 regimens shown